Allergan Announces FDA Acceptance Of Glaucoma Candidate NDA
Zacks Investment Research | Jul 18, 2019 06:26AM ET
Allergan plc (NYSE:AGN) announced that the FDA has accepted the new drug application (“NDA”) for its investigational biodegradable implant candidate, Bimatoprost SR. The NDA is seeking approval of the candidate for lowering intraocular pressure (“IOP”) in patients with open-angle glaucoma or ocular hypertension. A decision from the FDA is expected by the first half of 2020.
Bimatoprost SR will be the first sustained-release drop-free treatment option for the indication, if approved, in the United States.
Please note that Bimatoprost SR is the sustained-release formulation of Allergan’s marketed drug, Lumigan, approved for a similar indication.
Allergan’s shares have increased 21.6% this year so far against the industry ’s decrease of 4.5%.
The NDA was supported by data from two pivotal phase III ARTEMIS studies. The phase III studies compared Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension with timolol eye drops, a FDA standard comparator. Data from the studies showed that Bimatoprost SR reduced IOP by approximately 30% over the 12-week primary efficacy period, demonstrating non-inferiority to timolol.
After three months of treatment with Bimatoprost SR more than 80% of patients remained treatment free without any additional treatment to maintain IOP control for at least a year. Moreover, the candidate was well tolerated in patients.
Glaucoma can lead to irreversible vision loss. The targeted patient population represents a significant opportunity as there are 130 million globally suffering from glaucoma. This number is expected to increase to $148 million over the next four years. A treatment free period of nearly a year after three administrations of the implant will likely give patients freedom from more frequent administrations of currently available treatment options. This may lead to promising uptake for Bimatoprost SR.
We remind investors that, in March, Aerie Pharmaceuticals (NASDAQ:AERI) received FDA approval for Rocklatan, a combination of Aerie’s Rhopressa and Pfizer’s (NYSE:PFE) Xalatan, for a similar patient population targeted by Bimatoprost SR. Moreover, Ocular Therapeutix (NASDAQ:OCUL) is developing a sustained release formulation of travoprost for a similar indication.
Meanwhile, Allergan has more than 65 projects in mid-to-late stage development including six key programs including ubrogepant and atogepant for migraine and Abicipar for age-related macular degeneration ("AMD"). In May, schizophrenia drug, Vraylar’s (cariprazine) label was expanded to include under review and a decision is expected in the fourth quarter of 2019. The company’s biosimilar pipeline also provides significant growth opportunity.
Get The News You Want
However, the company is facing loss of exclusivity for many blockbuster products. Rising generic competition and anticipated branded competition for key drugs are likely to have an unfavorable impact on revenues. Hence, successful development of pipeline candidates is necessary for the company to offset branded/generic competition.
Zacks Rank
Allergan currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.